Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Myeloproliferative Disorders

pyrazines has been researched along with Myeloproliferative Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D1
Banti, A; Kaloutsi, V; Lazaridou, A; Terpos, E; Verrou, E; Zervas, K1
Walker, K1

Other Studies

3 other study(ies) available for pyrazines and Myeloproliferative Disorders

ArticleYear
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2010
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
    Leukemia research, 2007, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 5; Female; Humans; Interleukin-4; Interleukin-6; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Platelet Count; Pyrazines; Thrombocytosis; Tumor Necrosis Factor-alpha

2007
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines

2007